Ripretinib

CHEMBL4216467 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

510.4 g/mol

LogP

4.1

Phase

4

Ripretinib is a switch-control kinase inhibitor that broadly inhibits KIT and PDGFRA kinase activity regardless of mutation type through a dual mechanism of allosterically locking the activation loop in an inactive conformation and blocking ATP binding, overcoming resistance mutations at multiple sites. It is approved for the treatment of advanced gastrointestinal stromal tumors (GIST) that have progressed on prior treatment including imatinib.

分子量

510.4000 g/mol

LogP

4.10

TPSA

86.40 Å²

リピンスキーの五則

適合

治療領域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Non-Small Cell Lung Cancer Breast Cancer Prostate Cancer Colorectal Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

CCn1c(=O)c(-c2cc(NC(=O)Nc3ccccc3)c(F)cc2Br)cc2cnc(NC)cc21

InChI

InChI=1S/C24H21BrFN5O2/c1-3-31-21-12-22(27-2)28-13-14(21)9-17(23(31)32)16-10-20(19(26)11-18(16)25)30-24(33)29-15-7-5-4-6-8-15/h4-13H,3H2,1-2H3,(H,27,28)(H2,29,30,33)

Molecular Formula

C24H21BrFN5O2

HBD / HBA

3 / 5

回転可能結合数

5

重原子数

33

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

Ripretinib is a switch-control kinase inhibitor that broadly inhibits KIT and PDGFRA kinase activity regardless of mutation type through a dual mechanism of allosterically locking the activation loop in an inactive conformation and blocking ATP binding, overcoming resistance mutations at multiple sites. It is approved for the treatment of advanced gastrointestinal stromal tumors (GIST) that have progressed on prior treatment including imatinib.

Yes, Ripretinib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL4216467. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 71584930. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Ripretinib PillFYIで

構造

クイックデータ

分子式: C24H21BrFN5O2
同義語: 1

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.